Feature | TCT | October 15, 2020

TCT 2020 Late-breaking Study Presentations Announced

TCT 2020 Late-breaking Study trial Presentations Announced. #TCTconnect #TCT2020 #TCT

October 15, 2020 — The late-breaking studies are one of the hallmarks of the annual Transcatheter Cardiovascular Therapeutics (TCT) meeting. Here is the list of the 2020 virtual meeting presentations of groundbreaking, highly-impactful clinical research in interventional cardiology and structural heart advances. More than 30 late-breaking clinical trials and science will be presented. Each study has links to articles. 

Find more details at www.tctconnect.com/tct-program-late-breaking-trials-and-clinical-trials

 

Late-Breaking Clinical Trial Session I, Co-sponsored by JACC: Vulnerable Plaque Detection and Treatment 

Wednesday, October 14, 2020, Main Arena

   • PROSPECT II: A Prospective Natural History Study Using NIRS-IVUS Imaging in Patients With Acute Myocardial Infarction. Lecturer: David Erlinge

   • COMBINE (OCT–FFR): A Prospective Natural History Study Using OCT Imaging in Patients With Diabetes. Lecturer: Elvin Kedhi

   • PROSPECT ABSORB: A Randomized Trial of Interventional Treatment of Vulnerable Plaques With a Bioresorbable Stent. Lecturer: Gregg Stone

 

Late-Breaking Clinical Science Session I, Co-sponsored by Circulation: Acute Myocardial Infarction Interventions

Wednesday, October 14, 2020, Main Arena

   • NACMI: Outcomes From the North American COVID-19 STEMI Registry. Lecturer: Timothy Henry

   • COMPARE CRUSH: A Randomized Trial of Prehospital Crushed vs Uncrushed Prasugrel in STEMI. Lecturer: Georgios Vlachojannis

   • TICO-STEMI: A Randomized Trial of Ticagrelor Monotherapy vs Ticagrelor With Aspirin in STEMI. Lecturer: Byeong-Keuk Kim

   • Bivalirudin vs Heparin in Patients With Myocardial Infarction: An Individual Patient Data Pooled Analysis. Lecturer: Gregg Stone

 

Late-Breaking Clinical Trial Session II, Co-sponsored by JAMA

Thursday, October 15, 2020, Main Arena, 11 AM - 12 PM

SCOPE II: A Randomized Trial of Two Self-expanding TAVR Bioprostheses. Presented by Corrado Tamburino.

REFLECT II: A Randomized Trial of a Cerebral Embolic Protection Device During TAVR. Presented by Jeffrey Moses.

MITHRAS: A Randomized Trial of ASD Closure After TMVR. Presented by Philipp Lurz.

Late-Breaking Clinical Science Session II

Thursday, October 15, 2020, Main Arena, 12:30 – 1:30 PM

Disrupt CAD III: Safety and Effectiveness of Intravascular Lithotripsy for Treatment of Severe Coronary Calcification. Presented by Dean Kereiakes.

XIENCE 90/28: Assessment of Three-Month and One-Month DAPT After Everolimus-Eluting Stents in High-Bleeding Risk Patients. Presented by Roxana Mehran, Marco Valgimigli.

        VIDEO: Use of Shorten DAPT and the Xience Stent in High-bleeding Risk Patients — Press conference for trial and expert panel discussion

DEFINE-PCI: One-Year Outcomes in Patients With Post-PCI Residual Ischemia. Presented by Manesh Patel.

ULTIMATE: Three-Year Outcomes After IVUS-Guided vs Angiography Guided DES Implantation. Presented by Junjie Zhang.

 

Transcatheter Cardiovascular Therapeutics 2020 Late-Breaking Clinical Trial Session III, Co-sponsored by Lancet

Friday, October 16, 2020, 11 AM – 12:00 PM

FORECAST: A Randomized Trial of CTA and FFR-CT Decision-making in Patients With Chest Pain. Presented by Nick Curzen.

TARGET FFR: A Randomized Trial of Physiology-Guided PCI Optimization. Presented by Damien Collison.

DEFINE-FLOW: An Observational Study of Deferred Lesions After FFR and CFR Assessment. Presented by Nils Johnson.

 

Late-Breaking Clinical Science Session III

Friday, October 16, 2020, 12:30 PM – 1:30 PM

SOLVE-TAVI: One-Year Outcomes of a Factorial Randomized Trial of Self-expandable vs Balloon-expandable TAVR and General vs Local Anesthesia. Presented by Hans-Josef Feistritzer

STS/ACC TVT Registry: Cerebral Embolic Protection and TAVR Outcomes. Presented by David J. Cohen

MitraBridge: Outcomes of MitraClip Treatment as Bridge Therapy to Heart Transplantation. Presented by Cosmo Godino.

• Global EXPAND: One-Year Outcomes With Third Generation MitraClip NTR and XTR Systems. Presented by Saibal Kar.

 

Late-Breaking Clinical Trial Session IV, Co-sponsored by European Heart Journal

Saturday, October 17, 2020, Main Arena, 11 AM – 12:00 PM

Host-Reduce-Polytech-ACS: A Randomized Trial of Durable Polymer vs Bioabsorbable Polymer DES in Patients With Acute Coronary Syndromes. Presented by Hyo-Soo Kim.

COBRA-REDUCE: A Randomized Trial of a Thromboresistant Polyzene F-Coated Stent With 14 Days DAPT in High-Bleeding Risk Patients. Presented by Robert Byrne.

OPTIMIZE: A Randomized Trial of a Novel, Ultra Low Profile Fixed-Wire DES. Presented by Dean Kereiakes.

 

Late-Breaking Clinical Science Session IV

Saturday, October 17, 2020, Main Arena, 12:30 – 1:30 PM

IREMMI: Outcomes of MitraClip in Patients With Acute Mitral Regurgitation in AMI With and Without Cardiogenic Shock. Presented by Rodrigo Estevez-Loureiro.

SCOPE I: One-year Results From a Randomized Trial of Self-expanding vs Balloon-expandable TAVR. Presented by Thomas Walther.

TRANSIT: Treatment of Failed TAVR With TAVR. Presented by Luca Testa.

• PARTNER 2: Five-Year Follow-up From the Aortic Valve-in-Valve Registries. Presented by John Webb.

Endovascular 1: Late-Breaking Clinical Trials and Science

Sunday, October 18, 2020, Main Arena, 11 AM - 12:30 PM

VOYAGER PAD: Long-term Safety of Drug-Coated Devices in Peripheral Artery Revascularization. Presented by Connie Hess

IN.PACT BTK: A Randomzied Trial of Drug-Coated Balloon Angioplasty in the Infrapopliteal Arteries. Presented by Antonio Micari.

ILLUMENATE: Four-Year Results With a Low-Dose Paclitaxel Drug-Coated Balloon in De Novo And Restenotic Femoropopliteal Lesions. Presented by Andrew Holden.

TANGO: A Randomized Dose-Escalation Trial of Temsirolimus Adventitial Delivery to Improve Below the Knee Outcomes. Presented by Ehrin Armstrong.

FLASH Registry: Acute Hemodynamic Improvement With Percutaneous Mechanical Thrombectomy in a Real-world Pulmonary Embolism Population. Presented by Catalin Toma.

Anatomy of Human Accessory Renal Artery Peri-arterial Renal Sympathetic Nerve for Renal Denervation. Presented by Yu Sato.

 

Other TCT News and Studies:

VIDEO: What to Expect at the Virtual TCT 2020 Meeting — Interview with Juan F. Granada, M.D., CEO of the Cardiovascular Research Foundation (CRF)

COVID-19 Positive STEMI Patients Have Higher Mortality 

Restore EF Study Demonstrates Impella Supported High-Risk PCI Improves Left Ventricular Ejection Fraction

VIDEO: Interventional Structural Heart Advances Are Rapidly Expanding — Interview with Juan Granada, M.D.

VIDEO: Overview of Drug-coated Balloons — Interview with Juan Granada, M.D.

 

Conformal Medical CLAAS LAA Occluder Shows Promising Clinical Results at TCT 2020

ACC and CRF Create the Martin B. Leon Center for Cardiovascular Transformation

VIDEO: Survey Shows Large Disconnect in Medical Technology Across Continuum of Care — Interview with Nick West, M.D., chief medical officer for Abbott Vascular

VIDEO: Overview of Left Atrial Appendage (LAA) Closure Technology and New Innovations — Interview with Horst Sievert, M.D.

VIDEO: Artificial Intelligence May Improve Cath Lab Interventions — Interview with Nick West, M.D.,

 

Find more TCT news and video

 

 

 

Related Content

Hershey's Chocolate display with samples and coco pods at the American College of Cardiology (ACC) 2012 annual meeting. The company was making the case that chocolate can be good for your heart, which is now supported by several studies. Photo by Dave Fornell

Hershey's Chocolate display with samples and coco pods at the American College of Cardiology (ACC) 2012 annual meeting. The company was making the case that chocolate can be good for your heart, which is now supported by several studies. Photo by Dave Fornell

News | Cardiovascular Clinical Studies | July 22, 2020
July 22, 2020 — Eating chocolate at least once a week is linked with a reduced risk of heart disease, according to re
The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp